Key clinical point: The MitraClip appears to be safe and effective for correction of severe acute mitral regurgitation (MR) secondary to MI with cardiogenic shock in inoperable patients.
Major finding: Death or heart failure rehospitalization during a median 7 months follow-up occurred in 28% of the cardiogenic shock group and 25.6% of those without shock. Study details: This was an international prospective registry study of 93 consecutive surgically ineligible patients who underwent MitraClip implantation to correct severe acute MR secondary to MI, 50 of whom had cardiogenic shock.
Disclosures: The presenter reported receiving research grants from Abbott and serving as a consultant to that company, as well as to Boston Scientific.
Estevez-Loureiro R. TCT 2020, LBCS session IV.